Overview

A Study of AL8326 in Healthy Subjects

Status:
COMPLETED
Trial end date:
2025-05-17
Target enrollment:
Participant gender:
Summary
This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of \[14C\] AL8326 oral formulation containing approximately 60mg (200 Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.
Phase:
PHASE1
Details
Lead Sponsor:
Advenchen Laboratories Nanjing Ltd.